The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN223177     N-butyl-11- [(7R,8S,9S,13S,14S,17S)- 3,17...

Synonyms: CHEMBL1222035, CHEBI:40710, ICI-164384, AC1L2XGZ, LS-64831, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ICI M164384


High impact information on ICI M164384

  • This inhibition correlated with similar reductions in steady state-induced E-selectin mRNA levels, and was abrogated by the E2 antagonist ICI 164,384, demonstrating a specific, estrogen receptor-mediated effect [2].
  • E2 inhibited DNA replication in wild-type sense transfectants at a concentration of 10(-10) M and mutant sense transfectants at a concentration of 10(-8) M, and ICI 164,384 blocked this effect [3].
  • In similar experiments, we show that the anti-oestrogen, ICI 164,384, does not exhibit any oestrogenic activity and, therefore, acts always as a pure antagonist, even though it does not inhibit the activity of the isolated TAF-1 [4].
  • The specificity of the E2-induced transactivation of the reporter gene was shown by dose-dependent inhibition of transactivation by the pure E2 antagonist ICI 164,384 and by enhancement of the transactivation by simultaneous overexpression of the E2 receptor [5].
  • The induction of uterine DNA synthesis and phosphatidylinositol lipid turnover by EGF or administration of diethylstilbestrol (5 micrograms/kg), a potent estrogen, was attenuated by the estrogen receptor antagonist ICI 164,384 [6].

Chemical compound and disease context of ICI M164384


Biological context of ICI M164384


Anatomical context of ICI M164384

  • Both tamoxifen and ICI 164,384 behave as strong agonists in HeLa cells expressing the ER mutants [16].
  • The antiestrogen ICI 164,384 inhibited the proliferation of all three cell lines [17].
  • The levels of the cytokeratins 8, 18, and 19 bound to nuclear DNA or associated with the cytoskeleton of T-47D5 human breast cancer cells decreased when estrogens were depleted or the pure antiestrogen ICI 164,384 was added [18].
  • Three monoclonal antibodies, H222, H226 and D547, which provided evidence of the structural transformation and change in exposure of the functional domains of the oestrogen receptor from fetal guinea-pig uterus upon activation, were used to study the receptor bound to the anti-oestrogens 4-hydroxytamoxifen and ICI 164,384 [19].
  • Treatment with the anti-estrogen ICI 164,384 of oviduct cells in which FOSP-1 mRNA was pre-induced to high levels with the hormones caused a drastic reduction in nuclear ER and a total loss of FOSP-1 mRNA in 72 h [20].

Associations of ICI M164384 with other chemical compounds


Gene context of ICI M164384


Analytical, diagnostic and therapeutic context of ICI M164384


  1. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Dauvois, S., Danielian, P.S., White, R., Parker, M.G. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  2. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. Caulin-Glaser, T., Watson, C.A., Pardi, R., Bender, J.R. J. Clin. Invest. (1996) [Pubmed]
  3. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. Jiang, S.Y., Jordan, V.C. J. Natl. Cancer Inst. (1992) [Pubmed]
  4. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. Berry, M., Metzger, D., Chambon, P. EMBO J. (1990) [Pubmed]
  5. Human vascular smooth muscle cells contain functional estrogen receptor. Karas, R.H., Patterson, B.L., Mendelsohn, M.E. Circulation (1994) [Pubmed]
  6. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Ignar-Trowbridge, D.M., Nelson, K.G., Bidwell, M.C., Curtis, S.W., Washburn, T.F., McLachlan, J.A., Korach, K.S. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  7. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells. Chalbos, D., Philips, A., Galtier, F., Rochefort, H. Endocrinology (1993) [Pubmed]
  8. Transcriptional activation of heat shock protein 27 gene expression by 17beta-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists. Porter, W., Wang, F., Duan, R., Qin, C., Castro-Rivera, E., Kim, K., Safe, S. J. Mol. Endocrinol. (2001) [Pubmed]
  9. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Larsen, S.S., Egeblad, M., Jäättelä, M., Lykkesfeldt, A.E. Breast Cancer Res. Treat. (1999) [Pubmed]
  10. Effect of promegestone, tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on the oestrone sulphatase activity of human breast cancer cells. Chetrite, G., Varin, C., Delalonde, L., Pasqualini, J.R. Anticancer Res. (1993) [Pubmed]
  11. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Garcia, M., Derocq, D., Freiss, G., Rochefort, H. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  12. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Smith, C.L., Conneely, O.M., O'Malley, B.W. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  13. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Fawell, S.E., White, R., Hoare, S., Sydenham, M., Page, M., Parker, M.G. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
  14. Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Hurd, C., Khattree, N., Dinda, S., Alban, P., Moudgil, V.K. Oncogene (1997) [Pubmed]
  15. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. Weaver, C.A., Springer, P.A., Katzenellenbogen, B.S. Mol. Endocrinol. (1988) [Pubmed]
  16. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Mahfoudi, A., Roulet, E., Dauvois, S., Parker, M.G., Wahli, W. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  17. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. Love-Schimenti, C.D., Gibson, D.F., Ratnam, A.V., Bikle, D.D. Cancer Res. (1996) [Pubmed]
  18. Estrogen regulates the association of intermediate filament proteins with nuclear DNA in human breast cancer cells. Spencer, V.A., Coutts, A.S., Samuel, S.K., Murphy, L.C., Davie, J.R. J. Biol. Chem. (1998) [Pubmed]
  19. Studies on the activation of the oestrogen receptor bound to the anti-oestrogens 4-hydroxytamoxifen and ICI 164,384 by using three monoclonal antibodies. Giambiagi, N., Pasqualini, J.R. J. Mol. Endocrinol. (1991) [Pubmed]
  20. Autoinduction of estrogen receptor is associated with FOSP-1 mRNA induction by estrogen in primary cultures of Xenopus oviduct cells. Varriale, B., Tata, J.R. Mol. Cell. Endocrinol. (1990) [Pubmed]
  21. Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. Ylikomi, T., Bocquel, M.T., Berry, M., Gronemeyer, H., Chambon, P. EMBO J. (1992) [Pubmed]
  22. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Zou, A., Marschke, K.B., Arnold, K.E., Berger, E.M., Fitzgerald, P., Mais, D.E., Allegretto, E.A. Mol. Endocrinol. (1999) [Pubmed]
  23. Hormone induction of progesterone receptor (PR) messenger ribonucleic acid and activation of PR promoter regions in ovarian granulosa cells: evidence for a role of cyclic adenosine 3',5'-monophosphate but not estradiol. Clemens, J.W., Robker, R.L., Kraus, W.L., Katzenellenbogen, B.S., Richards, J.S. Mol. Endocrinol. (1998) [Pubmed]
  24. Cross-linking of estrogen receptor to chromatin in intact MCF-7 human breast cancer cells: optimization and effect of ligand. Wrenn, C.K., Katzenellenbogen, B.S. Mol. Endocrinol. (1990) [Pubmed]
  25. Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Jeng, M.H., Langan-Fahey, S.M., Jordan, V.C. Endocrinology (1993) [Pubmed]
  26. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J., Nilsson, S. Mol. Pharmacol. (1998) [Pubmed]
  27. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Ignar-Trowbridge, D.M., Pimentel, M., Parker, M.G., McLachlan, J.A., Korach, K.S. Endocrinology (1996) [Pubmed]
  28. The expression of interleukin-6 (IL-6), IL-6 receptor, and gp130-kilodalton glycoprotein in the rat decidua and a decidual cell line: regulation by 17beta-estradiol and prolactin. Deb, S., Tessier, C., Prigent-Tessier, A., Barkai, U., Ferguson-Gottschall, S., Srivastava, R.K., Faliszek, J., Gibori, G. Endocrinology (1999) [Pubmed]
  29. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Jeng, M.H., Jiang, S.Y., Jordan, V.C. Cancer Lett. (1994) [Pubmed]
  30. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Ignar-Trowbridge, D.M., Teng, C.T., Ross, K.A., Parker, M.G., Korach, K.S., McLachlan, J.A. Mol. Endocrinol. (1993) [Pubmed]
  31. Assessing the estrogenic and dioxin-like activities of chemicals and complex mixtures using in vitro recombinant receptor-reporter gene assays. Balaguer, P., Joyeux, A., Denison, M.S., Vincent, R., Gillesby, B.E., Zacharewski, T. Can. J. Physiol. Pharmacol. (1996) [Pubmed]
WikiGenes - Universities